Switch theme
Sign up to access all valuation multiples
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
2004
624
LTM Revenue $460M
LTM EBITDA $195M
$4.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ADMA Biologics has a last 12-month revenue (LTM) of $460M and a last 12-month EBITDA of $195M.
In the most recent fiscal year, ADMA Biologics achieved revenue of $426M and an EBITDA of $148M.
ADMA Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ADMA Biologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $460M | XXX | $426M | XXX | XXX | XXX |
| Gross Profit | $248M | XXX | $220M | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $195M | XXX | $148M | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 35% | XXX | XXX | XXX |
| EBIT | $165M | XXX | $139M | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 33% | XXX | XXX | XXX |
| Net Profit | $181M | XXX | $198M | XXX | XXX | XXX |
| Net Margin | 39% | XXX | 46% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ADMA Biologics's stock price is $20.
ADMA Biologics has current market cap of $4.7B, and EV of $4.7B.
See ADMA Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $4.7B | XXX | XXX | XXX | XXX | $0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ADMA Biologics has market cap of $4.7B and EV of $4.7B.
ADMA Biologics's trades at 11.1x EV/Revenue multiple, and 32.1x EV/EBITDA.
Equity research analysts estimate ADMA Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ADMA Biologics has a P/E ratio of 26.1x.
See valuation multiples for ADMA Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | 11.1x | XXX | XXX | XXX |
| EV/EBITDA | 24.4x | XXX | 32.1x | XXX | XXX | XXX |
| EV/EBIT | 28.7x | XXX | 34.2x | XXX | XXX | XXX |
| EV/Gross Profit | 19.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.1x | XXX | 24.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 43.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialADMA Biologics's last 12 month revenue growth is 22%
ADMA Biologics's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.1M for the same period.
ADMA Biologics's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ADMA Biologics's rule of X is 98% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ADMA Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | 580% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 57% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 98% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ADMA Biologics acquired XXX companies to date.
Last acquisition by ADMA Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . ADMA Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ADMA Biologics founded? | ADMA Biologics was founded in 2004. |
| Where is ADMA Biologics headquartered? | ADMA Biologics is headquartered in United States of America. |
| How many employees does ADMA Biologics have? | As of today, ADMA Biologics has 624 employees. |
| Who is the CEO of ADMA Biologics? | ADMA Biologics's CEO is Mr. Adam S. Grossman. |
| Is ADMA Biologics publicy listed? | Yes, ADMA Biologics is a public company listed on NAS. |
| What is the stock symbol of ADMA Biologics? | ADMA Biologics trades under ADMA ticker. |
| When did ADMA Biologics go public? | ADMA Biologics went public in 2013. |
| Who are competitors of ADMA Biologics? | Similar companies to ADMA Biologics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ADMA Biologics? | ADMA Biologics's current market cap is $4.7B |
| What is the current revenue of ADMA Biologics? | ADMA Biologics's last 12 months revenue is $460M. |
| What is the current revenue growth of ADMA Biologics? | ADMA Biologics revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of ADMA Biologics? | Current revenue multiple of ADMA Biologics is 10.3x. |
| Is ADMA Biologics profitable? | Yes, ADMA Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ADMA Biologics? | ADMA Biologics's last 12 months EBITDA is $195M. |
| What is ADMA Biologics's EBITDA margin? | ADMA Biologics's last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of ADMA Biologics? | Current EBITDA multiple of ADMA Biologics is 24.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
